A new review of existing data confirms that some common inhalers do not boost the life spans of people with the lung disease known as chronic obstructive pulmonary disease (COPD). In fact, these medicines may even raise the risk of pneumonia in patients with COPD. However, patients should not st

eyeGate Pharma recently received an award from Frost & Sullivan (F&S) recognising its development of ocular drug delivery technology. The ‘2008 North American Frost & Sullivan Technology Innovation ...

sanofi-Aventis' experimental heart drug Multaq will be reviewed by an independent expert panel in the US next March, marking a delay in a priority review by the health regulator. The company said that according to some analysts forecast, Multaq could yield more than $ 2 billion in annual sales.<

On the rebound from a salmonella scare last spring, local tomato growers have a fresh crop going to market. But some are more optimistic than others about this tomato season. Bob Spencer of West Coast...